StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Tuesday. The firm issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Performance

BIOL stock opened at $0.01 on Tuesday. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The firm has a market cap of $328,223.78, a PE ratio of 0.00 and a beta of 0.67. The firm’s 50 day moving average price is $0.01 and its 200-day moving average price is $0.04.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.